News

The Munich Eye2h
Breakthrough Treatment Approved for Rare Skin Disorder After 20 Years of Research
Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.
Q&A: Two decades of research lead to treatment for rare, painful skin condition
Patients with severe dystrophic epidermolysis bullosa, or EB, have skin so fragile, the slightest touch can lead to ...
MedPage Today on MSN4d
FDA OKs New Gene Therapy for Debilitating Skin Condition
Patients with the debilitating dermatologic condition are born with COL7A1 mutations in both gene copies, affecting the ...
BioPharma Dive4d
Abeona cell therapy approved by FDA for rare skin condition
Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...
Ross-shire Journal2d
Football legend Graeme Souness backs Black Isle girl: ‘You would think this was a disease sent by the devil himself’
A RARE condition that makes daily life a torment for a Black Isle girl was described by a Scottish football legend as “a ...
Medscape4d
FDA Approves First One-Time Topical Treatment for Recessive Dystrophic Epidermolysis Bullosa Wounds
In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...
Healio4d
FDA approves Zevaskyn for treatment of recessive dystrophic epidermolysis bullosa
The FDA has approved Zevaskyn for the treatment of recessive dystrophic epidermolysis bullosa, the company announced in a ...
MPR1d
Zevaskyn Approved for Recessive Dystrophic Epidermolysis Bullosa
The FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder.
BioSpace4d
Abeona Gets FDA Nod for Rare Skin Disease Gene Therapy
The condition, recessive dystrophic epidermolysis bullosa, causes chronic wounds and has an 84% mortality rate by age 40.
Yahoo Finance5d
Abeona cell therapy approved by FDA for rare skin condition
The agency cleared Abeona Therapeutics’ Zevaskyn for a form of epidermolysis bullosa, a rare disease that makes the skin susceptible to extensive and severe blistering. On a conference call ...